Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

ABSTRACT: This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.

DISEASE(S): Renal Cell Carcinoma (rcc),Colorectal Cancer (crc),Lung Cancer,Nsclc,Gastric Cancer,Carcinoma, Renal Cell,Mesothelioma,Bladder Cancer,Head And Neck Cancer,Metastatic Cancer,Uc (urothelial Cancer),Solid Tumors

PROVIDER: 2225246 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Immune checkpoint inhibitor-induced colitis

Project description:Immune checkpoint inhibitor-induced colitis

| PRJNA857579 | ENA

Comparative cardiac transcriptomics of immune checkpoint inhibitor induced myocarditis

Project description:Immune checkpoint inhibitors (ICIs) are improving cancer treatments strikingly. The raising use leads to the augmented occurrence of immune related events. Myocarditis is a rare, but severe form of these adverse events. Nine patients with proven ICI induced myocarditis were subjected to myocardial biopsy. The tissue was used for RNA-seq analyses.

2020-11-01 | E-MTAB-8867 | biostudies-arrayexpress

Restoring PD-1 immune checkpoint inhibitor response following IFNγ-driven adaptive resistance

Project description:Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by targeting molecules on immune cells that can inhibit the immune system's ability to attack cancer cells. One such checkpoint molecule is PD-1, which is found on the surface of T cells (a type of immune cell) and helps to prevent them from attacking healthy cells. When PD-1 binds to its ligand (a molecule on the surface of some cells), it sends a signal to the T cell to \\"turn off\\" and not attack the cell. This mechanism is important in preventing the immune system from attacking healthy cells, but it can also be exploited by cancer cells to avoid detection and destruction by the immune system. In this study YUMM2.1 mouse tumour cells were implanted subcutaneously. The effect of IFN-γ-pre-treatment, PARP14 inhibition and PD-1 antibody treatment are reported by RNA-seq.

2023-08-22 | E-MTAB-12872 | biostudies-arrayexpress

Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis

Project description:We conducted single-cell and T-cell receptor transcriptomic sequencing on the bronchoalveolar lavage fluid from five patients with grade ≥2 immune checkpoint inhibitor-related pneumonitis. Our analyses revealed a prominent enrichment of T cells in the bronchoalveolar lavage fluid of patients with immune checkpoint inhibitor-related pneumonitis.

2024-09-13 | GSE277136 | GEO

MDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma

Project description:MDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma

| PRJNA764915 | ENA

Comparative cardiac transcriptomics of immune checkpoint inhibitor induced myocarditis

Project description:Comparative cardiac transcriptomics of immune checkpoint inhibitor induced myocarditis

| PRJEB37155 | ENA

Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis

Project description:Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis

| PRJNA1160856 | ENA

Single-center study of CHeckpoint inhibitor Optimization based on PK/PD and ADA INvestigations in real-life clinical practice

Project description:Primary outcome(s): To reveal an association between exposure to immune checkpoint inhibitors and efficacy/safety in cancer patients.

| 2648154 | ecrin-mdr-crc

Colitis associated with immune checkpoint inhibitors

Project description:Colitis associated with immune checkpoint inhibitors

| PRJNA849977 | ENA

Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and dependent on IL23 and IFNgamma

Project description:Immune checkpoint inhibitor-induced colitis

| PRJEB65719 | ENA